- Home
- PHAT vs GDRX Comparison
PHAT vs GDRX Comparison
Compare PHAT & GDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAT | GDRX |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 868.9M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PHAT | GDRX |
|---|---|---|
| Price | $11.56 | $2.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $19.50 | $4.64 |
| AVG Volume (30 Days) | 898.5K | ★ 3.6M |
| Earning Date | 05-28-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 42.72 | ★ 125.00 |
| EPS | N/A | ★ 0.09 |
| Revenue | $175,110,000.00 | ★ $796,853,000.00 |
| Revenue This Year | $83.18 | $4.34 |
| Revenue Next Year | $61.43 | $7.05 |
| P/E Ratio | ★ N/A | $20.72 |
| Revenue Growth | ★ 216.93 | 0.57 |
| 52 Week Low | $2.21 | $1.79 |
| 52 Week High | $18.31 | $5.61 |
Technical Indicators
Market Signals| Indicator | PHAT | GDRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.53 | 45.48 |
| Support Level | $10.65 | $2.11 |
| Resistance Level | $12.77 | $2.87 |
| Average True Range (ATR) | 0.87 | 0.17 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 14.01 | 56.30 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About GDRX GoodRx Holdings Inc.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.